Table II.
Examples of therapeutic approaches in IGF and HPV-related cancers.
| Target | Method/Tool | Authors (ref.) |
|---|---|---|
| IGF-R | IGF-R specific mAbs | Shen et al (69), Miller and Yee (97), Hartog et al (98), Friedrich et al (99) |
| Small molecules targeting IGF-1R (tyrosine kinase inhibitors) | Gao et al (96), Arcaro (100) | |
| IGF-1 or IGF-2 | Ligand-neutralizing antibodies | Gao et al (96) |
| IGF-1R mRNA | Antisense RNA | Nakamura et al (105) |
| MicroRNA (miR-497) | Luo et al (108) | |
| Multiple targets for IGF axis | Multiple drug therapies | Baserga (104), Arcaro (100), Gao et al (96) |
| HPV E6/E7 | Synthetic interference RNA | Butz et al (110), Hall and Alexander (111) |
| Vector-borne siRNA | Gu et al (113), Zhou et al (115) | |
| shRNA via VLPs | Bousarghin et al (116) | |
| Immune system | Prophylactic vaccines containing VLPs (neutralizing Abs against HPV-L1) | Markowitz et al (118) |
| Therapeutic vaccines (inducing cytotoxic T lymphocytes ) | Berraondo et al (121), Peng et al (122), Da Silva et al (126) |